Last mentioned: Mar 18, 2026
Anticipated Regulatory Milestones
Potential for further regulatory filings based on ongoing Phase 3 data.
AACR Annual Meeting
Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.
Presentation Announcement
Zymeworks announces multiple abstracts accepted for AACR 2026.
Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
This page surfaces every story mentioning Ziihera (zanidatamab-hrii) across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Ziihera (zanidatamab-hrii) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |